Novel Insights Into DLAT's Role in Alzheimer's Disease-Related Copper Toxicity Through Microglial Exosome Dynamics

Xiang Ma1, Yusheng Sun1, Changchun Li2

  • 1Laboratory of Biochemistry and Pharmacy, Taiyuan Institute of Technology, Taiyuan, P. R. China.

PubMed
Abstract

Insights

Researchers discovered a new pathway in Alzheimer's disease (AD) where microglial exosomes transfer pyruvate kinase M2 (PKM2) to neurons, increasing dihydrolipoamide S-acetyltransferase (DLAT) and causing copper-induced neuronal death. Blocking this PKM2 transfer may slow AD progression.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pathology

Background:

  • Alzheimer's disease (AD) involves microglia and extracellular vesicles.
  • Copper toxicity's role in neuronal death and specific molecular pathways in AD is understudied.

Purpose of the Study:

  • Investigate the interaction between pyruvate kinase M2 (PKM2) and dihydrolipoamide S-acetyltransferase (DLAT).
  • Focus on copper-induced neuronal death in the context of Alzheimer's disease.

Main Methods:

  • Analyzed gene expression datasets for AD-related copper toxicity factors.
  • Validated dihydrolipoamide S-acetyltransferase (DLAT) role in 5xFAD mice.
  • Assessed microglial exosome-mediated PKM2 transfer to neurons in vitro.
  • Evaluated effects of inhibiting PKM2 transfer on DLAT expression and neuronal death.

Main Results:

  • Dihydrolipoamide S-acetyltransferase (DLAT) is critical in AD copper toxicity, linked to cognitive decline in 5xFAD mice.
  • Microglial exosomes transfer PKM2 to neurons, upregulating DLAT and increasing copper-induced neuronal death.
  • Inhibiting PKM2 transfer via exosomes reduced DLAT, mitigated neuronal death, and slowed AD progression.

Conclusions:

  • Uncovered a novel pathway involving microglial exosomes and the PKM2-DLAT interaction in copper-induced neuronal death.
  • Blocking PKM2 transfer presents potential therapeutic strategies for Alzheimer's disease.
  • This pathway offers new targets for reducing neuronal damage and slowing AD progression.

Related Concept Videos

Long-term Depression01:03

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
2.5K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165